New psychoactive substances (NPS) are a heterogeneous group of substances. They are
associated with a number of health and social harms on an individual and societal level …

Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

Psychoactive substances with chemical structures or pharmacological profiles that are
similar to traditional drugs of abuse continue to emerge on the recreational drug market …

Mental illness modeling is still a major challenge for scientists. Animal models of
schizophrenia are essential to gain a better understanding of the disease etiopathology and …

Novel psychoactive substances (NPS) represent significant analytical and interpretive
challenges to forensic and clinical toxicologists. Timely access to case reports and reports of …

BackgroundThe present paper provides an updated review of both the large number of
new/novel/emerging psychoactive substances (NPS) and their associated …

A new iridium catalyzed reductive coupling reaction of Grignard reagents and tertiary
amides affording functionalised tertiary amine products via an efficient and technically …

An important role of modern forensic and clinical toxicologists is to monitor the adverse
events of novel psychoactive substances (NPS). Following a prior review from 2013 to 2016 …

The use of several new psychoactive substances (NPS) has become very popular and is
posing global health risks. Chemically and pharmacologically diverse molecules are …

Background Consistent with postmortem findings in patients, most animal models for
schizophrenia (SCZ) present abnormal levels of parvalbumin (PV), a marker of fast-spiking …